| Protocols | ||
|---|---|---|
| 9 protocol(s) meet the specified criteria | ||
| Disease Site: Kidney | ||
| Protocol No. | Title | Status |
| ADVL1622 | Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors | Open |
| AMC-095 | A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma | Open |
| APEC1621SC | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) | Open |
| AREN1721 | A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups | Open |
| DFCI17-064/OMNIVORE | Phase II study of Optimized Management of NIVOlumab based on REsponse in patients with advanced renal cell carcinoma (OMNIVORE study) | Open |
| FADOI03-2016 | Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio Study | Open |
| MCC-16962 | A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors | Open |
| ML28897PRO/02 | My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents. | Open |
| NC-6300-001 | A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma | Open |